[go: up one dir, main page]

MX2020008791A - Ligandos de peptidos biciclicos multimericos. - Google Patents

Ligandos de peptidos biciclicos multimericos.

Info

Publication number
MX2020008791A
MX2020008791A MX2020008791A MX2020008791A MX2020008791A MX 2020008791 A MX2020008791 A MX 2020008791A MX 2020008791 A MX2020008791 A MX 2020008791A MX 2020008791 A MX2020008791 A MX 2020008791A MX 2020008791 A MX2020008791 A MX 2020008791A
Authority
MX
Mexico
Prior art keywords
polypeptides
peptide ligands
drug conjugates
multimers
peptides
Prior art date
Application number
MX2020008791A
Other languages
English (en)
Inventor
Peter Park
Gemma Mudd
Liuhong Chen
Rachid Lani
Kevin Mcdonnell
Punit Upadhyaya
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1802931.4A external-priority patent/GB201802931D0/en
Priority claimed from GBGB1805848.7A external-priority patent/GB201805848D0/en
Priority claimed from GBGB1818158.6A external-priority patent/GB201818158D0/en
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2020008791A publication Critical patent/MX2020008791A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a multimeros de polipeptidos que estan unidos covalentemente a andamios moleculares de manera que dos o mas bucles de peptidos se sostienen entre los puntos de union al andamio; la invencion tambien describe la multimerizacion de polipéptidos a traves de diversos enlazadores quimicos y bisagras de diversas longitudes y rigidez usando diferentes sitios de union dentro de los polipeptidos; en particular, la invencion describe multimeros de péptidos que son ligantes de alta afinidad y activadores de CD137; la invencion tambien incluye conjugados de farmacos que comprenden dichos peptidos, conjugados con uno o mas grupos efectores y/o funcionales, composiciones farmaceuticas que comprenden dichos ligandos de peptidos y conjugados de farmacos y el uso de dichos ligandos de peptidos y conjugados de farmacos para prevenir, suprimir o tratar una enfermedad o trastorno mediado por CD137.
MX2020008791A 2018-02-23 2019-02-22 Ligandos de peptidos biciclicos multimericos. MX2020008791A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1802931.4A GB201802931D0 (en) 2018-02-23 2018-02-23 Multimeric bicyclic peptide ligands
GBGB1805848.7A GB201805848D0 (en) 2018-04-09 2018-04-09 Multimeric bicyclic peptide ligands
GBGB1818158.6A GB201818158D0 (en) 2018-11-07 2018-11-07 Multimeric bicyclic peptide ligands
PCT/GB2019/050485 WO2019162682A1 (en) 2018-02-23 2019-02-22 Multimeric bicyclic peptide ligands

Publications (1)

Publication Number Publication Date
MX2020008791A true MX2020008791A (es) 2021-01-08

Family

ID=65767041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008791A MX2020008791A (es) 2018-02-23 2019-02-22 Ligandos de peptidos biciclicos multimericos.

Country Status (14)

Country Link
US (3) US10875894B2 (es)
EP (1) EP3755725A1 (es)
JP (2) JP2021514953A (es)
KR (1) KR20200128518A (es)
CN (1) CN111902429A (es)
AU (1) AU2019224659A1 (es)
BR (1) BR112020014576A2 (es)
CA (1) CA3091775A1 (es)
IL (1) IL276803A (es)
MX (1) MX2020008791A (es)
PH (1) PH12020551213A1 (es)
SA (1) SA520420008B1 (es)
SG (1) SG11202007678QA (es)
WO (1) WO2019162682A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017008575B1 (pt) 2014-10-29 2021-07-13 Bicyclerd Limited Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
CN118772242A (zh) 2017-08-04 2024-10-15 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
EP3755725A1 (en) 2018-02-23 2020-12-30 BicycleTX Limited Multimeric bicyclic peptide ligands
AU2019247795B2 (en) * 2018-04-04 2024-08-15 Bicycletx Limited Heterotandem bicyclic peptide complexes
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
US11613560B2 (en) 2019-05-09 2023-03-28 Bicycletx Limited Bicyclic peptide ligands specific for OX40
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP2022544246A (ja) * 2019-08-13 2022-10-17 バイスクルテクス・リミテッド 修飾された多量体二環式ペプチドリガンド
PT4464721T (pt) * 2019-10-03 2025-06-24 Bicycletx Ltd Complexos peptídicos bicíclicos heterotandem
GB201914872D0 (en) * 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
AR126029A1 (es) * 2020-11-13 2023-09-06 Bicycletx Ltd LIGANDOS DE PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EL RECEPTOR DE TRANSFERRINA 1 (TfR1)
WO2022148974A2 (en) * 2021-01-08 2022-07-14 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
US20240091368A1 (en) 2021-01-08 2024-03-21 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2022148971A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
CA3207009A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
US11904020B2 (en) * 2021-03-19 2024-02-20 Bicycletx Limited Bicyclic peptide ligands specific for TREM2
WO2022223969A1 (en) * 2021-04-20 2022-10-27 Bicycletx Limited Bicyclic peptide ligands specific for p-selectin
WO2024009108A1 (en) 2022-07-07 2024-01-11 Bicycletx Limited Anti-infective bicyclic peptide ligands
CN115991736B (zh) * 2022-07-21 2023-08-22 中国医学科学院北京协和医院 一种靶向cd137的多肽及其应用
WO2025046244A1 (en) * 2023-09-01 2025-03-06 Bicycletx Limited Tlr3 binding bicyclic peptide ligands
CN119176856B (zh) * 2024-11-22 2025-03-18 杭州诺泰诺和生物医药科技有限公司 Pegcetacoplan的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CA2595902C (en) 2005-01-24 2017-08-22 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
PL2257624T3 (pl) 2008-02-05 2012-09-28 Medical Res Council Sposoby i kompozycje
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
US10233251B2 (en) * 2015-02-22 2019-03-19 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
CN118772242A (zh) 2017-08-04 2024-10-15 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
EP3755725A1 (en) 2018-02-23 2020-12-30 BicycleTX Limited Multimeric bicyclic peptide ligands
AU2019247795B2 (en) 2018-04-04 2024-08-15 Bicycletx Limited Heterotandem bicyclic peptide complexes
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP2022544246A (ja) 2019-08-13 2022-10-17 バイスクルテクス・リミテッド 修飾された多量体二環式ペプチドリガンド
PT4464721T (pt) 2019-10-03 2025-06-24 Bicycletx Ltd Complexos peptídicos bicíclicos heterotandem

Also Published As

Publication number Publication date
US20230220008A1 (en) 2023-07-13
BR112020014576A2 (pt) 2020-12-08
PH12020551213A1 (en) 2021-04-19
US20190263866A1 (en) 2019-08-29
US20210101933A1 (en) 2021-04-08
US10875894B2 (en) 2020-12-29
KR20200128518A (ko) 2020-11-13
SG11202007678QA (en) 2020-09-29
AU2019224659A1 (en) 2020-10-15
US11542304B2 (en) 2023-01-03
IL276803A (en) 2020-10-29
JP2021514953A (ja) 2021-06-17
CA3091775A1 (en) 2019-08-29
JP2024023291A (ja) 2024-02-21
CN111902429A (zh) 2020-11-06
EP3755725A1 (en) 2020-12-30
SA520420008B1 (ar) 2024-02-05
WO2019162682A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
SA520420008B1 (ar) جزيئات ترابطية ببتيدية ثنائية الحلقات متعددة الوحدات
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
MX2021013669A (es) Ligandos peptidicos biciclicos especificos para ox40.
PH12020550929A1 (en) Bicyclic peptide ligands specific for epha2
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
NZ731185A (en) Bicyclic peptide ligands specific for mt1-mmp
MX2022004572A (es) Conjugados farmacologicos de ligandos peptidicos biciclicos.
MX2021006989A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
SA522431587B1 (ar) مــركب ببتيد ثنائي الحلقة متغاير الترادف
MX2023005624A (es) Ligandos peptidicos biciclicos especificos para el receptor de transferrina 1 (tfr1).
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
AU2019201173B2 (en) Novel polypeptides
WO2015155753A3 (en) Novel linkers and their uses in specific conjugation of drugs to biological molecule
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
NO20072997L (no) Posisjonsstyrt omdanning av FVIII
WO2022148974A3 (en) Bicyclic peptide ligands specific for nk cells
JP2017523781A5 (es)
WO2020132366A4 (en) T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2020247388A3 (en) Il-2alpha receptor subunit binding compounds
EA202091991A1 (ru) Мультимерные бициклические пептидные лиганды
AU2018278809A1 (en) Recombinant ROBO2 proteins, compositions, methods and uses thereof
EA202190105A1 (ru) Бициклические пептидные лиганды, специфичные к нектину-4
WO2005007682A3 (en) A peptide and a pharmaceutical composition, and their medical applications
EA202091375A1 (ru) БИЦИКЛИЧЕСКИЕ ПЕПТИДНЫЕ ЛИГАНДЫ, ОБЛАДАЮЩИЕ СПЕЦИФИЧНОСТЬЮ К EphA2
AR113966A1 (es) LIGANDOS PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EphA2